Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

EBOS Group (EBO NZ): Strong Industry Positioning and Acquisitions to Drive Growth

Equity Capital Markets

<ul>
<li>Ebos Group aims to raise A$ 100 million through a retail offer to partly fund the acquisition of LifeHealthcare. The acquisition creates an exciting platform to drive future growth.</li>
<li>Defensive product mix enabled EBOS to successfully navigate pandemic driven uncertainty and post record high ROCE of 18% in FY21. Balance Sheet remains healthy, with net debt/EBITDA of 0.85x.</li>
<li>FY22 starts on a strong note, with revenue and NPAT growing at over 10% and 14%, y/y, respectively. Dividend is expected at 60–80% of NPAT in FY22.</li>
</ul>


Ebos Group aims to raise A$ 100 million through a retail offer to partly fund the acquisition of LifeHealthcare. The acquisition creates an exciting platform to drive future growth.
Defensive product mix enabled EBOS to successfully navigate pandemic driven uncertainty and post record high ROCE of 18% in FY21. Balance Sheet remains healthy, with net debt/EBITDA of 0.85x.
FY22 starts on a strong note, with revenue and NPAT growing at over 10% and 14%, y/y, respectively. Dividend is expected at 60–80% of NPAT in FY22.


EBOS Group (EBO NZ): Raising Capital to Fund Acquisition; Attractive Bet on Australasian Healthcare

Ebos Group Ltd

EBOS Group (EBO NZ): Raising Capital to Fund Acquisition; Attractive Bet on Australasian Healthcare